Statins at 70: The Trial That Rewrites the Rules
# Statins at 70: The Evidence Just Changed A world-first clinical trial led by Australian researchers has found that statins — the cholesterol-lowering drugs taken by hundreds of millions globally — can safely and meaningfully reduce the risk of heart attacks and strokes in healthy people aged over 70, a population that has historically been excluded from the evidence base underpinning statin prescriptions.
Statins at 70: The Trial That Rewrites the Rules
A world-first clinical trial led by Australian researchers has found that statins — the cholesterol-lowering drugs taken by hundreds of millions globally — can safely and meaningfully reduce the risk of heart attacks and strokes in healthy people aged over 70, a population that has historically been excluded from the evidence base underpinning statin prescriptions.
The trial, reported by The Guardian, found low rates of side effects among otherwise healthy older participants, directly challenging the clinical hesitancy that has kept many GPs from prescribing statins to elderly patients without prior cardiovascular events. The reluctance was never irrational — it was simply unevidenced in either direction. Now it has evidence, and the evidence cuts one way.
Cardiovascular disease remains the leading cause of death globally, and adults over 70 carry a disproportionate share of that burden. The trial's finding matters not just clinically but economically: statins are among the cheapest drugs in existence, costing pennies per day in generic form, and widespread preventive use in older cohorts could reduce hospitalisation costs at scale.
What happens next will be determined not by science but by health system inertia — the gap between what trials prove and what guidelines eventually permit. That gap, in medicine as in everything else, is where people die waiting.
